Join some of the Cambridge Network team and fellow members for an afternoon of networking over tea, cakes and fruit at Cambridge Network Connect (previously known as Making the Most of Membership). If you want to meet like-minded companies and some new people, come and join us for a couple of hours. We’d love to meet you too. No presentations this time (ok, just a short welcome and introduction from our CEO)!
Event timings are:
Guest blog by RSM.
As life sciences businesses grow and evolve, so too does the complexity of their data and third-party access landscape. From startups to mid-sized enterprises, strong cyber security fundamentals are essential to protecting research and intellectual property, safeguarding investor funds and confidence, and ensuring long-term success.
Inaphaea BioLabs, the translational contract research organisation based at MediCity Nottingham, has announced the promotion of Melissa Barr to Head of Scientific Operations.
Melissa joined Inaphaea in 2023 as Lead Scientist. Since then, she has played an instrumental role in delivering preclinical drug discovery projects across oncology and women’s health, as well as leading a team of scientists on-site.
by Alicia Gailliez, Business Development Manager, One Nucleus
Over the past 12 months, One Nucleus has organised 41 events in partnership with 48 sponsors and supporters. These regular sessions were complemented by our flagship events, Genesis, ON Helix and the One Nucleus Annual Awards Dinner.
Looking ahead to 2025
A lack of access to capital, particularly proof-of-concept funding, is stifling growth in the UK’s university spinout sector, according to a recent survey conducted by Symbiosis IP, a part of professional services group Gateley.
Described by one respondent as a “broken funding model”, the sector’s lack of funding and difficulty securing much-needed investment capital, particularly outside of the South East, are two of the most urgent issues facing the university spinout sector.
At CHARM Therapeutics, we are pioneering the future of medicine design through the use of our protein-ligand intelligence platform to deliver next generation small molecule therapeutics.
At CHARM Therapeutics, we are pioneering the future of medicine design through the use of our protein-ligand intelligence platform to deliver next generation small molecule therapeutics.
AMSBIO announce a new range of Synthetic Nanodiscs that enable preparation of multi-pass transmembrane proteins in their active form, revolutionizing the future of membrane protein research and drug development. Membrane Proteins account for more than 60% of all FDA-approved drug targets and 90% of antibody-based drug targets. Many traditional sample preparation methods struggle with challenges in obtaining water-soluble and bioactive forms of multi-pass transmembrane proteins.
Recent top global hires for large-cap, mid-cap, and public companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech in the second half of 2024.
CEO/ C-suite/ Board
Job type: Permanent, Full-time
Location: Oxford
Right to work: Sponsorship available